Managing Alzheimer’s disease requires an intricate understanding of available treatments. Michelle Sorweid, DO, MPH, sheds light on anti-amyloid antibody therapy, how it works, and what patients are ...

On Tuesday, the FDA approved Eli Lilly and Co’s (NYSE:LLY) Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer’s disease. Once-monthly, Kisunla is ...

A new study provides a well-needed glimmer of hope for treating Alzheimer’s disease. Focusing on a genetic form of early-onset dementia called dominantly inherited Alzheimer’s disease, scientists have ...

After a lull of nearly 2 decades, the Food and Drug Administration (FDA) has approved some novel drugs for the treatment of Alzheimer’s disease since 2021. Most of these drugs are antibody therapies ...

Antibody therapy restoring microglial function Lecanemab, already FDA-approved, is one such anti-amyloid antibody therapy designed to target amyloid-beta plaques and slow down the progression of ...

Reviewed by Anton Porsteinsson, MD, Director of the University of Rochester Alzheimer’s Disease Care, Research and Education Program (AD-CARE) in New York; and the first William B. and Sheila Konar ...

– Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) – – Gantenerumab is the first and only anti-amyloid antibody being investigated for ...

Voyager Therapeutics is tripling down on its Alzheimer’s disease franchise, this time with a gene therapy aimed at amyloid-beta plaques. The company broke the news on its second-quarter earnings call ...

Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid plaques and delays cognitive decline. Researchers from VIB and KU Leuven have ...

A new entrant in the race to shepherd antibodies for Alzheimer’s disease across the blood-brain barrier has emerged. Korsana Biosciences has catapulted out of stealth with $175 million and designs for ...